Drugs Made In America Acquisition Corp. Files 8-K
Ticker: DMAAR · Form: 8-K · Filed: Feb 25, 2025 · CIK: 2028614
| Field | Detail |
|---|---|
| Company | Drugs Made In America Acquisition Corp. (DMAAR) |
| Form Type | 8-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-securities, corporate-events
TL;DR
DMAA filed an 8-K on Feb 25 for unregistered equity sales & other events. Keep an eye on this.
AI Summary
Drugs Made In America Acquisition Corp. filed an 8-K on February 25, 2025, reporting unregistered sales of equity securities and other events. The filing date indicates the report was submitted on February 25, 2025, with the earliest event reported on February 18, 2025. The company's principal executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301.
Why It Matters
This 8-K filing indicates potential changes in the company's equity structure or significant operational events that could impact investors.
Risk Assessment
Risk Level: medium — Unregistered sales of equity securities can sometimes signal financial distress or dilution, requiring further investigation.
Key Players & Entities
- Drugs Made In America Acquisition Corp. (company) — Registrant
- February 18, 2025 (date) — Date of earliest event reported
- February 25, 2025 (date) — Date of Report
- 1 East Broward Boulevard, Suite 700 Fort Lauderdale, FL 33301 (address) — Principal Executive Offices
- 001-42467 (company_id) — SEC File Number
FAQ
What specific type of equity securities were sold unregistered?
The filing does not specify the type of equity securities sold unregistered, only that it falls under Item 3.02.
What are the 'Other Events' reported in this filing?
The filing does not detail the specific 'Other Events' beyond listing it as an item, requiring further review of the full document.
What is the significance of the 'Financial Statements and Exhibits' being included?
This suggests that financial information or supporting documents relevant to the reported events are being provided with the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 18, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Drugs Made In America Acquisition Corp. (DMAAR).